PAX3 and rhabdomyosarcoma: We applied the described model-selection strategy and goodness-of-fit test to the following datasets: (1) CD4+ naïve T cells (9850 cells); and (2) CD4+ memory T cells (9578 cells), both of which were generated on the GemCode platform (10× Genomics, Pleasanton, CA, USA) [8], and 3) Rh41 cells, a human PAX3-FOXO1 positive alveolar rhabdomyosarcoma (ARMS) cell line (6875 cells) prepared in-house on the Chromium platform (10× Genomics).